SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.